Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights

World Journal of Gastroenterology

Volumn 20, Issue 12, 2014, Pages 3135-3145

  Chan, Stephen L ^a,b   Yeo, Winnie ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b State Key Laboratory in Oncology in South China   (Hong Kong)

Author keywords

Bio logics; Clinical trial; Liver neoplasms; Staging; Systemic treatment

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BELINOSTAT; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; DOVITINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FOLFOX; HISTONE DEACETYLASE INHIBITOR; INC 280; IPILIMUMAB; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PEXASTIMOGENE DEVACIREPVEC; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SIPULEUCEL T; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ARGININE; MTOR PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CHEMOEMBOLIZATION; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; LIVER CELL CARCINOMA; MELANOMA; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN DEGRADATION; SYSTEMIC THERAPY; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; CLINICAL TRIAL (TOPIC); IMMUNOTHERAPY; LIVER NEOPLASMS; METABOLISM; ONCOLOGY; PROCEDURES; TRENDS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ARGININE; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MEDICAL ONCOLOGY; PROTO-ONCOGENE PROTEINS C-MET; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84896977908     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i12.3135     Document Type: Article

References (90)

1. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowen-thal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Suni-tinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075 [PMID: 24081937 DOI: 10.1200/JCO.2012.45.8372]
2. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslid-suk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ez-zeddine R, Walters I, Cheng AL. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced he-patocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31: 3517-3524 [PMID: 23980084 DOI: 10.1200/JCO.2012.48.4410]
3. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Far-toux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31: 3509-3516 [PMID: 23980090 DOI: 10.1200/JCO.2012.47.3009]
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109 [PMID: 15466206]
5. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-574 [PMID: 17160391]
6. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL. Safety and effcacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10: 794-800 [PMID: 19586800 DOI: 10.1016/ S1470-2045(09)70171-8]
7. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lah-denranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomark-ers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035 [PMID: 19470923 DOI: 10.1200/JCO.2008.20.9908]
8. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Kamath A, Marathe P, D'Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fbro-blast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 51: 1976-1980 [PMID: 18288793]
9. Raoul JL, Finn RS, Kang YK, Park JW, Harris R, Coric V, Donica M, Walters I. An open-label phase II study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009; 27: 15. Available from: URL: http://meetinglibrary.asco.org/con-tent/33909-65
10. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17: 1973-1983 [PMID: 21349999 DOI: 10.1158/1078-0432. CCR-10-2011]
11. Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McK-eegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP. Phase 2 trial of lini-fanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2013; 119: 380-387 [PMID: 22833179 DOI: 10.1002/cncr.27758]
12. Cainap C, Qin S, Huang WT, a b, c d, e f, G Se, d f. Phase III trial of linifanib vs sorafenib in patients with advanced hepa-tocellular carcinoma (HCC). J Clin Oncol 2012; 30 (suppl 34): abstr 249. Available from: URL: http://meetinglibrary.asco.org/content/105448-133
13. Pediaditakis P, Lopez-Talavera JC, Petersen B, Monga SP, Michalopoulos GK. The processing and utilization of hepato-cyte growth factor/scatter factor following partial hepatectomy in the rat. Hepatology 2001; 34: 688-693 [PMID: 11584364]
14. Huh CG, Factor VM, Sánchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004; 101: 4477-4482 [PMID: 15070743]
15. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the tumor and its micro-environment by a dual-function decoy Met receptor. Cancer Cell 2004; 6: 61-73 [PMID: 15261142]
16. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest 2002; 109: 857-862 [PMID: 11927611]
17. Kiss A, Wang NJ, Xie JP, Thorgeirsson SS. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997; 3: 1059-1066 [PMID: 9815784]
18. Osada S, Kanematsu M, Imai H, Goshima S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 544-549 [PMID: 18613405]
19. Ljubimova JY, Petrovic LM, Wilson SE, Geller SA, Deme-triou AA. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J His-tochem Cytochem 1997; 45: 79-87 [PMID: 9010472]
20. Okano J, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver 1999; 19: 151-159 [PMID: 10220746]
21. You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011; 54: 879-889 [PMID: 21618573 DOI: 10.1002/hep.24450]
22. Adjei AA, Schwartz B, Garmey E. Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers. Oncologist 2011; 16: 788-799 [DOI: 10.1634/theoncologist.2010-0380]
23. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63 [PMID: 23182627 DOI: 10.1016/ S1470-2045(12)70490-4]
24. Verslype C, Cohn A, Kelley R, Yang T, Su WC, Ramies DA, Lee Y, Shen X, van Cutsem E. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012; 30 Suppl: abstr 4007
25. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501 [PMID: 12094235 DOI: 10.1038/nrc839]
26. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Al-sinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Ll-ovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983; 1883e1-e11 [PMID: 18929564]
27. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torben-Son M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-8425 [PMID: 15623621 DOI: 10.1158/1078-0432.CCR-04-0941]
28. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyer-hardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellu-lar carcinoma. Cancer 2011; 117: 5094-5102 [PMID: 21538343 DOI: 10.1002/cncr.26165]
29. Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival. Available from: URL: http://wwwnovartiscom/newsroom/media-releases/en/2013/1721562shtml
30. Chan SL, Mo F, Hui EP, Koh J, Chu CM, Hui J, Li L, Loong H, Ho WM, Ma B, To KF, Yu S, Chan AT, Yeo W. A phase I study of temsirolimus as novel therapeutic drug for patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2013; 31 Suppl: abstr e15048. Available from: URL: http://meetinglibrary.asco.org/content/113480-132
31. Yeo W.S.L. C, Mo F, Hui EP, Koh J, Li L, Hui J, Chu CM, Loong H, Yu S. A phase I/II study of mTOR inhibtior tem-sirolimus in patients with unresectable hepatocellular carcinoma (HCC). Ann Oncol 2013; 24 Supp 4: 32
32. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-339 [PMID: 21386836]
33. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirsch-baum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-5417 [PMID: 19826128 DOI: 10.1200/JCO.2008.21.6150]
34. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R, Pazdur R. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007; 13: 2318-2322 [PMID: 17438089 DOI: 10.1158/1078-0432.CCR-06-2672]
35. Ma BB, Sung F, Tao Q, Poon FF, Lui VW, Yeo W, Chan SL, Chan AT. The preclinical activity of the histone deacety-lase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs 2010; 28: 107-114 [PMID: 19172229]
36. Carlisi D, Lauricella M, D'Anneo A, Emanuele S, Angileri L, Di Fazio P, Santulli A, Vento R, Tesoriere G. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009; 45: 2425-2438 [PMID: 19643600]
37. Carlisi D, Vassallo B, Lauricella M, Emanuele S, D'An-neo A, Di Leonardo E, Di Fazio P, Vento R, Tesoriere G. Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 2008; 32: 177-184 [PMID: 18097557]
38. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multi-center phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012; 30: 3361-3367 [PMID: 22915658 DOI: 10.1200/ JCO.2011.41.2395]
39. New M, Olzscha H, Liu G, Khan O, Stimson L, McGouran J, Kerr D, Coutts A, Kessler B, Middleton M, La Thangue NB. A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death Differ 2013; 20: 1306-1316 [PMID: 23703321 DOI: 10.1038/ cdd.2013.47]
40. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, Duvic M, Kerr DJ, La Thangue NB. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 2010; 107: 6532-6537 [PMID: 20308564 DOI: 10.1073/pnas.0913912107]
41. Tapiero H, Mathé G, Couvreur P, Tew KD. I. Arginine. Biomed Pharmacother 2002; 56: 439-445 [PMID: 12481980]
42. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004; 100: 826-833 [PMID: 14770441 DOI: 10.1002/cncr.20057]
43. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW. Arginine deprivation and ar-gininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010; 126: 2762-2772 [PMID: 20104527 DOI: 10.1002/ijc.25202]
44. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010; 103: 954-960 [PMID: 20808309 DOI: 10.1038/sj.bjc.6605856]
45. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, Izzo F. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepato-cellular carcinoma. J Clin Oncol 2010; 28: 2220-2226 [PMID: 20351325 DOI: 10.1200/JCO.2009.26.7765]
46. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007; 67: 309-317 [PMID: 17210712 DOI: 10.1158/0008-5472.CAN-06-1945]
47. Lam TL, Wong GK, Chow HY, Chong HC, Chow TL, Kwok SY, Cheng PN, Wheatley DN, Lo WH, Leung YC. Recombi-nant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 2011; 24: 366-376 [PMID: 21029397 DOI: 10.1111/j.1755-148X.2010.00798.x]
48. Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SY, Arnold S, Cheng PN, Wheatley DN, Lo WH, Leung YC. Pe-gylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int 2009; 9: 9 [PMID: 19374748 DOI: 10.1186/1475-2867-9-9]
49. Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, Chow TL, Kwok SY, Poon RT, Wheatley DN, Lo WH, Leung YC. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett 2009; 277: 91-100 [PMID: 19138817 DOI: 10.1016/ j.canlet.2008.11.031]
50. Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res 2013; 19: 6678-6685 [PMID: 24030702 DOI: 10.1158/1078-0432. CCR-13-1721]
51. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Al-backer LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203: 883-895 [PMID: 16606670 DOI: 10.1084/jem.20051776]
52. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical beneft in melanoma patients. Clin Cancer Res 2013; 19: 5300-5309 [PMID: 24089443 DOI: 10.1158/1078-0432. CCR-13-0143]
53. Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci 2012; 8: 767-775 [PMID: 23185184 DOI: 10.5114/aoms.2012.31610]
54. Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol 2012; 27: 862-872 [PMID: 22369685 DOI: 10.1111/j.1440-1746.2012.07096.x]
55. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-fnding trial with pharmacokinetic and biomarker correlates. Ann Oncol 2013; 24: 1900-1907 [PMID: 23519998 DOI: 10.1093/annonc/mdt109]
56. Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 2013; 59: 1271-1277 [PMID: 23928403 DOI: 10.1016/j.jhep.2013.07.029]
57. Zhu AX, Rosmorduc O, Evans J, Ross P, Santoro A, Carriho FJ, Leberre M, Jensen MR, Meinhardt G, Kang Y. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocel-lular carcinoma (HCC). Ann Oncol 2012; ESMO 2012 Annual Meeting LBA2. Available from: URL: http://abstracts.web_ges.com/viewing/view.php?congress=esmo2012&congress_id=370&publication_id=917
58. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850 [PMID: 19139433 DOI: 10.1200/ JCO.2008.18.3301]
59. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: fnal results of a phase II trial. Oncology 2012; 82: 67-74 [PMID: 22327795 DOI: 10.1159/000335963]
60. Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C. Phase 2 study of bevaci-zumab plus erlotinib in patients with advanced hepatocellu-lar cancer. Cancer 2012; 118: 2424-2430 [PMID: 21953248 DOI: 10.1002/cncr.26556]
61. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radio-logic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27: 446-452 [PMID: 19064965]
62. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fuorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538 [PMID: 16234567]
63. Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in he-patocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol 2009; 5: 889-899 [PMID: 19663737 DOI: 10.2217/fon.09.64]
64. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31: 3501-3508 [PMID: 23980077 DOI: 10.1200/JCO.2012.44.5643]
65. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10: 2878-2882 [PMID: 15334691]
66. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemo-embolization. Acta Radiol 2008; 49: 523-529 [PMID: 18568538 DOI: 10.1080/02841850801958890]
67. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Trans-catheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-921 [PMID: 18177453]
68. Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu R, Sun X. Antian-giogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer 2007; 121: 416-424 [PMID: 17330237]
69. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 3960-3967 [PMID: 21911714 DOI: 10.1200/JCO.2011.37.1021]
70. Lencioni R, Llovet R, Han G, Tak WY, Yang J, Leberre M, Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placebo in combination with transarterial chemoemboliza-tion (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012; 30 suppl 4: abstr LBA154. Available from: URL: http://meet-inglibrary.asco.org/content/87707-115
71. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012; 48: 1452-1465 [PMID: 22240282 DOI: 10.1016/j.ejca.2011.12.006]
72. Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep 2012; 14: 257-266 [PMID: 22434314 DOI: 10.1007/s11912-11012-10233-11910]
73. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 Suppl 1: S20-S37 [PMID: 18304676]
74. Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. A study of circulating in-terleukin 10 in prognostication of unresectable hepatocellu-lar carcinoma. Cancer 2012; 118: 3984-3992 [PMID: 22180222 DOI: 10.1002/cncr.26726]
75. Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT, Mok TS, Yeo W. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepa-tocellular carcinoma in an Asian population. J Gastroenterol Hepatol 2011; 26: 340-347 [PMID: 21261725 DOI: 10.1111/ j.1440-1746.2010.06329.x]
76. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK. Advanced hepatocel-lular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010; 28: 2889-2895 [PMID: 20458042 DOI: 10.1200/JCO.2009.25.9895]
77. Torzilli G, Donadon M, Marconi M, Palmisano A, Del Fab-bro D, Spinelli A, Botea F, Montorsi M. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg 2008; 143: 1082-1090 [PMID: 19015467 DOI: 10.1001/archsurg.143.11.1082]
78. Chang WT, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, Hsia CY, Lui WY, King KL, Lee SD. Hepatic resection can provide long-term survival of patients with non-early-stage hepato-cellular carcinoma: extending the indication for resection? Surgery 2012; 152: 809-820 [PMID: 22766361 DOI: 10.1016/ j.surg.2012.03.024]
79. Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol 2013; 9: 2-5 [PMID: 23418846 DOI: 10.1111/ajco.12061]
80. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M. The ART of decision making: retreatment with transarterial chemoem-bolization in patients with hepatocellular carcinoma. Hepa-tology 2013; 57: 2261-2273 [PMID: 23316013 DOI: 10.1002/ hep.26256]
81. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishika-wa S, Tsutsumi S, Sonoda K, Totsuka H, Shirakihara T, Sakamoto H, Wang L, Ojima H, Shimada K, Kosuge T, Okusaka T, Kato K, Kusuda J, Yoshida T, Aburatani H, Shibata T. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 2011; 43: 464-469 [PMID: 21499249 DOI: 10.1038/ng.804]
82. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Naka-mura Y, Tsunoda T, Shibata T, Nakagawa H. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012; 44: 760-764 [PMID: 22634756 DOI: 10.1038/ng.2291]
83. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu XY, Liu RF, Fei QL, Chen H, Cai B, Zhou B, Xiao HS, Qin LX, Han ZG. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012; 44: 1117-1121 [PMID: 22922871 DOI: 10.1038/ng.2391]
84. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694-698 [PMID: 22561517 DOI: 10.1038/ ng.2256]
85. Tao Y, Ruan J, Yeh SH, Lu X, Wang Y, Zhai W, Cai J, Ling S, Gong Q, Chong Z, Qu Z, Li Q, Liu J, Yang J, Zheng C, Zeng C, Wang HY, Zhang J, Wang SH, Hao L, Dong L, Li W, Sun M, Zou W, Yu C, Li C, Liu G, Jiang L, Xu J, Huang H, Li C, Mi S, Zhang B, Chen B, Zhao W, Hu S, Zhuang SM, Shen Y, Shi S, Brown C, White KP, Chen DS, Chen PJ, Wu CI. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci USA 2011; 108: 12042-12047 [PMID: 21730188 DOI: 10.1073/pnas.1108715108]
86. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogel-stein B, Diaz LA, Velculescu VE. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012; 4: 162ra154 [PMID: 23197571 DOI: 10.1126/scitranslmed.3004742]
87. Chan KC, Jiang P, Chan CW, Sun K, Wong J, Hui EP, Chan SL, Chan WC, Hui DS, Ng SS, Chan HL, Wong CS, Ma BB, Chan AT, Lai PB, Sun H, Chiu RW, Lo YM. Noninvasive detection of cancer-associated genome-wide hypomethyl-ation and copy number aberrations by plasma DNA bisulfte sequencing. Proc Natl Acad Sci USA 2013; 110: 18761-18768 [PMID: 24191000 DOI: 10.1073/pnas.1313995110]
88. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, Siu SS, Chan WC, Chan SL, Chan AT, Lai PB, Chiu RW, Lo YM. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013; 59: 211-224 [PMID: 23065472 DOI: 10.1373/ clinchem.2012.196014]
89. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514]
90. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497 DOI: 10.1016/ S1470-2045(08)70285-7]